Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma (Q80764931)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

title

Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

H de Lavallade

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

J El-Cheikh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

C Faucher

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

S Fürst

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

A-M Stoppa

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

D Coso

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

R Bouabdallah

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

C Chabannon

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

J-A Gastaut

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

D Blaise

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

M Mohty

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

25 February 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

3 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

953-960

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18297115%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/bmt.2008.22

3 January 2020

exact match

0 references

cites work

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

https://api.crossref.org/works/10.1038%2FBMT.2008.22

1 reference

7 January 2021

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

A comparison of allografting with autografting for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Graft-versus-myeloma effect

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Graft-versus-myeloma effect in two cases

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.22

7 January 2021